Home
About Us
About Us
Board of directors
Team
Our Products
Pipeline
LN-Cast-01
LN-008 si-MASP2
Our Science
miRNA based Castling
siRNA and miRNA
Non-coding RNA
siRNA Advantages
Contact Us
News
Latest News
News
22 January 2026
Lepton announced today that it has filed a patent titled “Methods for Enhanced Genome Editing.”
News
14 January 2026
Lepton announced today that its manuscript introducing Castling, a novel therapeutic concept for rewiring pathological gene-expression networks enabled by its TRIPLE™ technology, has been submitted for peer review.
News
30 May 2024
LEPTON Pharmaceuticals LTD and TAmiRNA GmbH enhance their collaboration
News
23 August 2023
Lepton Announced Completion of Filing for a Patent Application Extending the Usage of Its Castling Breakthrough Technologies
News
26 July 2022
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement
News
14 February 2022
Lepton signs Consulting Agreement with Cell Therapy Expert Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall founding director, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, Ca, USA
News
04 February 2022
Prof. Malcolm K Brenner, M.D., Ph.D. Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy Houston, TX US agreed to consult to Lepton
News
01 February 2022
Lepton signs Consulting Agreement with Dr. Paz Einat
